BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 23, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 28, 2010
View Archived Issues
YM Could Bring in Up to $7.75M in Controlled Equity Financing
Read More
Biotie Goes Partner Hunting After Roche Pulls Out of Mab Project
Read More
Adventrx Plunges on Delay in Cancer Drug Resubmission
Read More
Come See Us at BIO 2010 And Get Your Chicago Hat
Read More
Other News To Note
Read More
Stock Movers
Read More
Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data
Impressive, though early stage, Phase I data already has Pluristem Therapeutics Inc. setting the stage for Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. (BioWorld Today)
Read More
AB Science Brings in €27.5M After Scaling Back its IPO
No Abstract
Read More
Clinic Roundup
Read More
